BRUSSELS – Although the medtech industry warns of a greater ”capacity crisis,” the sector shouldn’t be expecting to have products approved locally in Denmark for sale in the EU any time soon.
This message comes from one of the central players in the extensive approval process, the Danish Medicines Agency. The authority tells MedWatch that the case processing of an application from German Tüv Süd to become a notified body in Denmark isn’t anticipated to be concluded before summer 2023.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.